ABSTRACT
AIM: We conducted a case-control study in China to clarify the association between the XRCC1-Arg399Gln polymorphism and HCC risk. METHODS: A total of 202 cases and 236 controls were selected from the the Affiliated Hospital of Qingdao University from May 2008 to May 2010. Assessment of the XRCC1-Arg399Gln polymorphism was based upon duplex polymerase-chain-reactions with the confronting-two-pair primer (PCR- CTPP) method. All analyses were performed using the STATA statistical package. RESULTS: A significant increase in risk was associated with the Arg/Gln genotype (adjusted OR 1.55, 95%CI=1.03-2.57) compared with Arg/ Arg. However, the Gln/Gln genotype had non-significant increased risk of HCC with adjusted OR (95%CI) of 1.34(0.67-2.38). There was also a significant increase with the Arg/Gln genotype among HCC patients above 50 years old (OR=1.95, 95% CI=1.14-3.57). Additionally, the risk of HCC was moderately increased in drinkers with Arg/Gln genotype compared with never drinkers, and the adjusted OR (95% CI) was 1.89 (1.13-3.45). CONCLUSION: This study demonstrated that a polymorphism in a DNA repair gene may influence the risk of HCC. The XRCC1 codon Arg/Gln was this associated with an increased risk of HCC, especially in patients above 50 years old and/or with a drinking habit.
Subject(s)
Carcinoma, Hepatocellular/genetics , DNA Repair , DNA-Binding Proteins/genetics , Liver Neoplasms/genetics , Adult , Age Factors , Alcohol Drinking , Alleles , Amino Acid Substitution , Carcinoma, Hepatocellular/epidemiology , Case-Control Studies , China/epidemiology , Female , Genetic Predisposition to Disease , Genotype , Humans , Liver Neoplasms/epidemiology , Male , Middle Aged , Polymorphism, Single Nucleotide , Risk Factors , X-ray Repair Cross Complementing Protein 1ABSTRACT
Alterations of human leukocyte antigen (HLA) class II molecules are relevant to the development of breast cancer and metastatic progression. However, the role of HLA class II polymorphisms in the pathogenesis and progression of breast cancer is unclear. This study aimed to investigate the association between HLA class II variants and breast cancer susceptibility and prognosis in a Chinese population. Sixteen variants in HLA class II were detected with the Sequenom MassArray® iPLEX System in 216 breast cancer patients and 216 healthy controls. An association analysis based on unconditional logistic regression was carried out to determine the odds ratio (OR) and 95% confidence interval (95% CI) for each SNP. Stratified analysis by oestrogen receptor (ER) and progesterone receptor (PR) status was also performed. Among 16 variants, only seven conformed to Hardy-Weinberg proportions in the controls. None of these seven variants showed statistically significant differences between the case and control groups in this Han Chinese population. However, chr6_32737733, a variant in HLA-DQB1, showed significant associations with both ER-negative and PR-negative breast cancer in the best fit to the dominant model. Furthermore, another significant correlation was seen between chr6_32606112, a variant in HLA-DRB5, and PR positivity. These results indicate that although no breast cancer risk variants in HLA class II were found in this Chinese population, HLA-DQB1 chr6_32737733 may be involved in determining a poor prognosis, whereas HLA-DRB5 chr6_32606112 may relate to a good prognosis.
Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/immunology , Genes, MHC Class II , Breast Neoplasms/mortality , Case-Control Studies , China , Disease Progression , Female , Genetic Variation , HLA-DQ beta-Chains/genetics , HLA-DQ beta-Chains/immunology , HLA-DRB5 Chains/genetics , HLA-DRB5 Chains/immunology , Humans , Middle Aged , Polymorphism, Single Nucleotide , PrognosisABSTRACT
OBJECTIVE: In order to explore the expression of RalB (ras related; GTP binding protein B) in mammal eucaryotic cell, we prepared and characterized monoclonal antibodies against RalB. METHODS: Hybridomas were generated by the fusion with Sp2/0 myelomas and spleen cells, which were from mice immunized with RalB recombinant proteins. The monoclonal antibodies against RalB were then used to identify the expression of RalB in mammal eucaryotic cell, including normal hepatic cell and hepatoma carcinoma cells, by Western blot and Immunohistochemistry. RESULTS: Two hybridoma cell lines, F001, F002, had been produced, each of which stably secrets antibodies against RalB. Subclass of IgG are both belonged to IgG1. Immunohistochemistry demonstrated that RalB was presented in plasma membrane of hepatoma tissue. Western-blot showed that RalB was expressed in all concerned cell. CONCLUSION: The monoclonal antibodies against RalB protein have been successfully prepared, which should provide useful reagent for further investigation into the biological function of RalB.
